Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 736

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)

Open access
Terpos, Evangelos, Engelhardt, Monika, Cook, Gordon, Gay, Francesca, Mateos, Maria-Victoria, Ntanasis-Stathopoulos, Ioannis, van de Donk, Niels W. C. J., Avet-Loiseau, Hervé, Hajek, Roman, Vangsted, Annette Juul, Ludwig, Heinz, Zweegman, Sonja, Moreau, Philippe, Einsele, Hermann, Boccadoro, Mario, San Miguel, Jesus, Dimopoulos, Meletios A., Sonneveld, Pieter·2020·Leukemia

Abstract

Patients with multiple myeloma (MM) seem to be at increased risk for more severe COVID-19 infection and associated complications due to their immunocompromised state, the older age and comorbidities. The European Myeloma Network has provided an expert consensus statement in order to guide therapeutic decisions in the era of the COVID-19 pandemic. Patient education for personal hygiene and social distancing measures, along with treatment individualization, telemedicine and continuous surveillance for early diagnosis of COVID-19 are essential. In countries or local communities where COVID-19 infection is widely spread, MM patients should have a PCR test of nasopharyngeal swab for SARS-CoV-2 before hospital admission, starting a new treatment line, cell apheresis or ASCT in order to avoid ward or community spread and infections. Oral agent-based regimens should be considered, especially for the elderly and frail patients with standard risk disease, whereas de-intensified regimens for dexamethasone, bortezomib, carfilzomib and daratumumab should be used based on patient risk and response. Treatment initiation should not be postponed for patients with end organ damage, myeloma emergencies and aggressive relapses. Autologous (and especially allogeneic) transplantation should be delayed and extended induction should be administered, especially in standard risk patients and those with adequate MM response to induction. Watchful waiting should be considered for standard risk relapsed patients with low tumor burden, and slow biochemical relapses. The conduction of clinical trials should continue with appropriate adaptations to the current circumstances. Patients with MM and symptomatic COVID-19 disease should interrupt anti-myeloma treatment until recovery. For patients with positive PCR test for SARS-CoV-2, but with no symptoms for COVID-19, a 14-day quarantine should be considered if myeloma-related events allow the delay of treatment. The need for surveillance for drug interactions due to polypharmacy is highlighted. The participation in international COVID-19 cancer registries is greatly encouraged.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41375-020-0876-z

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Cited by

See all 736

Metadata

Authors
Terpos, E., Engelhardt, M., Cook, G., Gay, F., Mateos, M.-V., Ntanasis-Stathopoulos, I., van de Donk, N. W. C. J., Avet-Loiseau, H., Hajek, R., Vangsted, A. J., Ludwig, H., Zweegman, S., Moreau, P., Einsele, H., Boccadoro, M., San Miguel, J., Dimopoulos, M. A., & Sonneveld, P.
Venue
Leukemia
Published
2020-05-22
Volume
34
Issue
8
Pages
2000-2011
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
OpenAlex
W3028330817
Cited by
736
References
55
FWCI
18.50
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). https://app.cochat.ai/papers/10.1038/s41375-020-0876-z
The paper
Terpos, E., Engelhardt, M., Cook, G., Gay, F., Mateos, M.-V., Ntanasis-Stathopoulos, I., van de Donk, N. W. C. J., Avet-Loiseau, H., Hajek, R., Vangsted, A. J., Ludwig, H., Zweegman, S., Moreau, P., Einsele, H., Boccadoro, M., San Miguel, J., Dimopoulos, M. A., & Sonneveld, P. (2020). Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia. https://doi.org/10.1038/s41375-020-0876-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.